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ABSTRACT 
Nipah virus is an RNA virus that is part of the Paramyxovidae family that was first identified as a zoonotic pathogen after an 
outbreak involving severe respiratory illness in pigs and encephalitic disease in humans in Malaysia and Singapore in 1998 and 
1999. Nipah virus can cause a range of mild to severe disease in domestic animals such as pigs. Nipah virus infection in humans 
causes a range of clinical presentations, from asymptomatic infection (subclinical) to acute respiratory infection and fatal 
encephalitis. Nipah virus can be transmitted to humans from animals (bats, pigs), and can also be transmitted directly from human-
to-human. Fruit bats of the Pteropodidae family are the natural host of Nipah virus. There is no treatment or vaccine available for 
either people or animals. A recombinant measles virus (rMV) vaccine expressing NiV envelope glycoproteins is proposed but is still 
under trial. The primary treatment for humans is supportive care. Nipah virus is an emerging threat to the human life with history of 
outbreaks chiefly in Bangladesh, India & Malaysia. Categorized as zoonotic biosafety level 4 (BSL4) agent depending upon the 
geographic locations of outbreaks, it is responsible of case mortality between 40% to 100% in both humans and animals thus one of 
the most deadly virus known to infect humans. The present review article cover current potential therapeutics in India against nipah 
virus infection. 
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INTRODUCTION 
Nipah virus was first recognized in 1999 during an 
outbreak among pig farmers in Kampung Sungai Nipah, 
Malaysia. No new outbreaks have been reported in 
Malaysia and Singapore since 1999. NiV (Nipah virus) 
was first recognized in Bangladesh in 2001 and nearly 
annual outbreaks have occurred in that country since, 
with disease also identified periodically in eastern India
1-
2
. Other regions may be at risk for NiV infection, as 
serologic evidence for NiV has been found in the known 
natural reservoir (Pteropus bat species) and several other 
bat species in a number of countries, including 
Cambodia, Thailand, Indonesia, Madagascar, Ghana and 
the Philippines. Nipah virus (NiV) is an emerging 
zoonotic virus (a virus transmitted to humans from 
animals)
3-4
. In infected people, Nipah virus causes a 
range of illnesses from asymptomatic (subclinical) 
infection to acute respiratory illness and fatal 
encephalitis. NiV can also cause severe disease in 
animals such as pigs, resulting in significant economic 
losses for farmers. Although Nipah virus has caused 
only a few outbreaks, it infects a wide range of animals 
and causes severe disease and death in people, making it 
a public health concern. More than 60% of the newly 
identified infectious agents that have affected people 
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over the past few decades have been caused by 
pathogens originating from animals or animal products. 
Of these zoonotic infections, 70% originate from 
wildlife. Bats have been recognized to be important 
reservoir of zoonotic viruses, including Ebola, Marburg, 
SARS and Melaka viruses
5
. In this context, Nipah Virus 
(NiV) represents another new emerging zoonosis, one of 
the most important bat-borne pathogens discovered in 
recent history. In 1998 a dangerous new virus emerged 
in Malaysia
6
. Initially thought to be a form of Japanese 
Encephalitis, it was later identified as a new zoonotic 
disease and named Nipah after the village of “Sungai 
Nipah” where it was first identified. Similarly, at the 
beginning in pigs it was confused with Classical swine 
fever. In infected people, Nipah virus causes severe and 
commonly lethal illness. It can also cause severe disease 
in animals such as pigs, and may require the application 
of stamping out policy, thus resulting in significant 
economic losses for farmers
7
. The National Centre for 
Disease Control has issued high alert across the country 
after an outbreak of the Nipah virus (NiV) infection in 
Kerala.  
Since their initial recognition, Nipah and Hendra viruses 
have repeatedly re-emerged. In total, 13 HeV (Hendra 
virus) outbreaks have occurred in Australia in 1994, 
1999, 2004, and 2006–2009, and have always involved 
horses as an intermediate host with some human 
infections including four fatalities, the most recent in 
September 2009
8-10
. NiV has also repeatedly caused 
spill-over events involving hundreds of human cases 
since 1998 with at least nine recognized occurrences 
primarily in Bangladesh and India since 2001 with the 
most recent in March 2008
11
. Several of the more recent 
NiV outbreaks have had higher rates of acute respiratory 
distress syndrome in conjunction with encephalitis, 
epidemiological findings consistent with multiple rounds 
of person-to-person transmission, higher case fatality 
rates (∼75%), and direct transmission of virus from 
flying foxes to humans via contaminated food has been 
demonstrated
12-13
. In addition to their highly pathogenic 
nature, the henipaviruses are also distinguished from all 
other paramyxoviruses by their unusually broad host 
tropism. Host cell infection by NiV and HeV requires 
two membrane-anchored envelope glycoproteins; the 
attachment (G) glycoprotein which binds the viral 
receptor, and the fusion (F) glycoprotein which drives 
virus-host cell membrane merger
14
. The henipavirus G 
glycoprotein lacks hemagglutinin and neuraminidase 
activities and the F glycoprotein is a typical class I 
fusion glycoprotein
15-16
. The host cell membrane 
anchored proteins, ephrin-B2 and ephrin-B3 ligands, 
have been shown to be the receptors employed by the 
henipaviruses
17-22
. There are presently no licensed 
therapeutics available to treat infection caused by the 
henipaviruses. Recently, some scientist isolated and 
extensively characterized a neutralizing human 
monoclonal antibody (hmAb), m102.4, which 
recognizes the receptor binding domain of the HeV and 
NiV G glycoproteins. This human monoclonal antibody 
potently neutralized both viruses in vitro and maintained 
its biological activity in vivo suggesting its possible 
utility as a passive therapeutic modality following 
henipavirus infection
23
. 
 
Figure 1: Nipah falls under the category of Zoonotic 
diseases like Ebola, HIV, mad cow disease and rabies, 
which can spread from animals to humans. 
EPIDEMIOLOGY 
Intensive agriculture has been implicated in the 
transmission of the deadly Nipah virus to humans. 
Between the 1970s and the 1990s, pig and mango 
production tripled in Malaysia. Mango trees were 
typically planted near pig enclosures, attracting fruit bats 
to the area. As bats fed and roosted in the trees, nearby 
livestock became infected with Nipah virus, which 
eventually spread to farm labourers. It is assumed that 
the geographic distribution of Henipaviruses overlaps 
with that of Pteropus category. This hypothesis was 
reinforced with the evidence of Henipavirus infection in 
Pteropus bats from Australia, Bangladesh, Cambodia, 
China, India, Indonesia, Madagascar, Malaysia, Papua 
New Guinea, Thailand and Timor-Leste
24
. Furthermore, 
the detection of antibodies against Nipah and Hendra 
viruses in straw-colored fruit bat (Eidolon helvum), 
indicates that these viruses might be present within the 
geographic distribution of Pteropodidae bats, not only in 
Asia, but extended to Africa, Arabian Peninsula coast, 
Middle-East, Cyprus and Southern Turkey
25-26
.
 
Table 1: Henipavirus Outbreaks and Pteropus Distribution Map 
Countries with reported outbreak of at risk based on 
serological evidence or molecular detection in Pteropus bats 
Australia, Bangladesh, Cambodia, China, India, 
Indonesia, Madagascar, PNG Taiwan, Thailand 
Home range of Pteropus bats Bhutan, Brunei, China, India, Indonesia, Laos, 
Madagascar, Myanmar, Nepal, Philippines, PNG, 
Singapore, Taiwan, Thailand, Vietnam 
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TRANSMISSION 
NiV is a zoonotic virus (a virus transmitted to humans 
from animals). During the initial outbreaks in Malaysia 
and Singapore, most human infections resulted from 
direct contact with sick pigs or their contaminated 
tissues. Transmission is thought to have occurred via 
respiratory droplets, contact with throat or nasal 
secretions from the pigs, or contact with the tissue of a 
sick animal. In the Bangladesh and India outbreaks, 
consumption of fruits or fruit products (e.g. raw date 
palm juice) contaminated with urine or saliva from 
infected fruit bats was the most likely source of 
infection. Limited human to human transmission of NiV 
has also been reported among family and care givers of 
infected NiV patients. During the later outbreaks in 
Bangladesh and India, Nipah virus spread directly from 
human-to-human through close contact with people's 
secretions and excretions. In Siliguri, India, transmission 
of the virus was also reported within a health-care 
setting (nosocomial), where 75% of cases occurred 
among hospital staff or visitors. From 2001 to 2008, 
around half of reported cases in Bangladesh were due to 
human-to-human transmission through providing care to 
infected patients
27-28
. 
 
Figure 2: Nipah is fatal in a large number of cases and 
has a fatality rate between 40-75% according to the 
WHO. According to a research conducted in 
Bangladesh, it had a fatality rate of 54%, i.e. 315 deaths 
occurred out of the 582 cases studied. 
SIGNS AND SYMPTOMS 
In Human: Infection with Nipah virus is associated 
with encephalitis (inflammation of the brain). After 
exposure and an incubation period of 5 to 14 days, 
illness presents with 3-14 days of fever and headache, 
followed by drowsiness, disorientation and mental 
confusion. These signs and symptoms can progress to 
coma within 24-48 hours. Some patients have a 
respiratory illness during the early part of their 
infections, and half of the patients showing severe 
neurological signs showed also pulmonary signs. During 
the Nipah virus disease outbreak in 1998-99, 265 
patients were infected with the virus. About 40% of 
those patients who entered hospitals with serious 
nervous disease died from the illness.  Long-term 
sequelae following Nipah virus infection have been 
noted, including persistent convulsions and personality 
changes. Latent infections with subsequent reactivation 
of Nipah virus and death have also been reported 
months and even years after exposure 
29-30
. 
 In domestic animals: Nipah outbreaks in pigs and 
other domestic animals (horses, goats, sheep, cats and 
dogs) were first reported during the initial Malaysian 
outbreak in 1999. Many pigs had no symptoms, but 
others developed acute febrile illness, laboured 
breathing, and neurological symptoms such as 
trembling, twitching and muscle spasms. 
Other species: Limited clinical information exists for 
other species. In dogs, distemper-like syndrome was 
described with pyrexia, depression, dyspnoea and 
conjunctivitis with purulent ocular-nasal discharge. 
Severe disease with mortality was also reported. NiV 
infection was confirmed by immuno histochemical 
examination of 1 dead and 1 dying dog from the 
epidemic area in Malaysia. Both showed histologic 
evidence of severe disease. Morbidity in dogs during 
outbreaks in Malaysia was interestingly high, with a 
seroprevalence from 15% up to 46%. Nipah affected 
cats were observed on farms during outbreaks in 
Malaysia and some of these resulted in death. 
Experimental intranasal and oral inoculation of cats 
produced clinical disease characterized by acute febrile 
course with respiratory complications. Fruit bats show 
no serious signs of infection. 
Diagnosis: Laboratory diagnosis of a patient with a 
clinical history of NiV can be made during the acute and 
convalescent phases of the disease by using a 
combination of tests. Virus isolation attempts and real 
time polymerase chain reaction (RT-PCR) from throat 
and nasal swabs, cerebrospinal fluid, urine, and blood 
should be performed in the early stages of disease. 
Antibody detection by ELISA (IgG and IgM) can be 
used later on. In fatal cases, immunohistochemistry on 
tissues collected during autopsy may be the only way to 
confirm a diagnosis. 
CONTROLLING NIPAH VIRUS IN DOMESTIC 
WILDLIFE 
Currently, there are no vaccines available against Nipah 
virus. Routine and thorough cleaning and disinfection of 
pig farms (with appropriate detergents) may be effective 
in preventing infection. If an outbreak is suspected, the 
animal premises should be quarantined immediately. 
 Culling of infected animals – with close supervision of 
burial or incineration of carcasses – may be necessary to 
reduce the risk of transmission to people. Restricting or 
banning the movement of animals from infected farms 
to other areas can reduce the spread of the disease. As 
Nipah virus outbreaks in domestic animals have 
preceded human cases, establishing an animal health 
surveillance system, using a One Health approach, to 
detect new cases is essential in providing early warning 
for veterinary and human public health authorities 
31
. 
Reducing the risk of contagion in Human Being 
In the absence of a licensed vaccine, the only way to 
reduce infection in people is by raising awareness of the 
risk factors and educating people about the measures 
they can take to reduce exposure to and decrease 
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infection from NiV. Public health educational messages 
should focus on the following: 
 Reducing the risk of bat-to-human transmission: 
Efforts to prevent transmission should first focus on 
decreasing bat access to date palm sap and to other 
fresh food products. Keeping bats away from sap 
collection sites with protective coverings (e.g., 
bamboo sap skirts) may be helpful. Freshly collected 
date palm juice should be boiled and fruits should be 
thoroughly washed and peeled before consumption.  
 Reducing the risk of animal-to-human 
transmission: Gloves and other protective clothing 
should be worn while handling sick animals or their 
tissues, and during slaughtering and culling 
procedures. As much as possible, people should 
avoid being in contact with infected pigs.  
 Reducing the risk of human-to-human 
transmission: Close unprotected physical contact 
with Nipah virus-infected people should be avoided. 
Regular hand washing should be carried out after 
caring for or visiting sick people.  
Controlling infection in health-care settings: Health-
care workers caring for patients with suspected or 
confirmed NiV infection, or handling specimens from 
them, should implement standard infection control 
precautions for all patients at all times. As human-to-
human transmission in particular nosocomial 
transmission have been reported, contact and droplet 
precautions should be used in addition to standard 
precautions. Samples taken from people and animals 
with suspected NiV infection should be handled by 
trained staff working in suitably equipped laboratories
32-
33
. 
RECENT STATUS OF POTENTIAL 
THERAPEUTICS AND VACCINE 
DEVELOPMENT 
The recent emergence of these viruses and the sporadic 
nature of disease outbreaks have made the development 
and testing of vaccines and therapeutics for henipavirus 
infections a low commercial priority. However, the 
development of such countermeasures is a crucial 
component of any preparedness plan against an outbreak 
or emergence whether deliberate or natural. Vaccines 
have been used very successfully to control other well-
known and debilitating paramyxovirus infections 
including measles and mumps infection of humans and 
rinderpest virus infection of cattle. Vaccination with an 
attenuated live measles virus vaccine began in 1963 and 
was highly successful in reducing the infection rate with 
measles virus. In the United States alone, the first 20 
years of vaccination is estimated to have prevented 52 
million cases of the disease, 17,400 cases of mental 
retardation and 5200 deaths
34
. As a result of vaccination 
the United States has been declared free of endemic 
measles
35
. Importantly, an historic announcement in 
May 2011 declared rinderpest as the first animal disease 
ever to be eradicated by humankind 
36
. Vaccination was 
a central plank of the campaign to eradicate the virus. 
Successful resistance to paramyxovirus infection that is 
conferred by vaccination is commonly mediated by an 
adaptive immune response to viral surface 
proteins/glycoproteins particularly for infections 
associated with a viraemic phase such as those caused 
by the measles virus and the mumps virus
37-39
. 
Consequently, vaccine development for the 
henipaviruses has focused on the viral F and G envelope 
glycoproteins either expressed in a recombinant virus or 
as a recombinant subunit immunogen. Hamsters 
vaccinated with recombinant vaccinia viruses encoding 
NiV G or F were protected against a lethal challenge 
with NiV. However a strong anamnestic response to the 
challenge virus suggested that vaccination did not 
prevent virus replication
40
. Similarly, pigs vaccinated 
with canarypox viruses encoding either NIV G or F 
were protected against a lethal NiV infection and 
although virus was not reisolated from any tissues low 
levels of viral RNA were detected in several samples
41
. 
The NiV envelope proteins F (fusion) and G 
(glycoprotein) were chosen for vaccine development, 
based on work by Guillaume et al
42
. with a vaccinia 
virus-based recombinant vaccine expressing the NiV F 
and G proteins in golden hamsters and on knowledge of 
immunity to other paramyxoviruses. For example, 
antibodies against the measles virus F protein contribute 
to virus neutralization, likely by preventing fusion of the 
virus with the cell membrane at the time of virus entry
43
. 
Antibodies against measles virus hemagglutinin (H), the 
attachment protein of the virus analogous to the Nipah 
virus G protein, are the most important neutralizing 
antibodies
44-45
. In addition, the F and G proteins may be 
involved in inducing the CD8
+
 cytotoxic T-cell response 
to NiV, analogous to the role of measles virus proteins 
H and F
46
. A previously developed NiV early-infection 
model in pigs was used in the challenge part of the 
work. The purpose of this study was to obtain 
preliminary data on the efficacy of a veterinary vaccine 
against NiV in target species by using for the first time 
in pigs the canarypox virus vector, which is proven and 
approved for commercial use in domestic animals. The 
aim of the vaccine was not only to prevent disease in 
animals but most importantly to prevent virus shedding, 
in order to protect the human population by breaking the 
chain of transmission and to stop virus spread in swine 
herds, especially in areas of endemicity. On the other 
hand, in areas where the virus is not endemic, where it 
may be introduced intentionally or by accident, the 
vaccination may be used in outbreak control, with 
emphasis on the rapid establishment of protective 
immunity in swine herds following vaccination. To meet 
the specific requirements, different optimal vaccination 
doses/regimens may need to be designed
47
. Several 
studies have also been carried out with a HeV 
recombinant soluble G glycoprotein (sG)-based subunit 
immunogen (HeVsG). In one experimental study, cats 
survived a lethal NiV challenge with no clinical signs 
and the data supported the development of sterilizing 
immunity in this animal model. In a second study 
carried out in cats, virus was reisolated from one 
vaccinated animal and viral RNA was detected in the 
brains of several animals receiving the two highest 
doses of vaccine
48-49
. The authors speculated that the 
detection of genome in the brain in the face of 
significant levels of neutralizing antibody prior to 
challenge indicated that 'a persistent infection might 
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occur despite pre-existing immunity'. In a vaccine 
antigen dose sparing study, ferrets immunized with 
HeVsG survived an otherwise lethal HeV challenge. 
Here, all vaccine antigen doses prevented clinical 
disease and there was no anamnestic antibody response 
detected following challenge, nor could any challenge 
virus be reisolated from any animal
50
. While all three of 
these studies utilized HeVsG as the vaccine immunogen, 
variations in adjuvant used, immunogen dose and 
challenge virus dose make it difficult to directly 
compare the experimental outcomes. However, the 
results of two of three studies indicate that it is possible 
to prevent establishment of a HeV infection by 
vaccination, and indeed all three studies indicated that 
vaccination could prevent clinical illness. 
Development of an effective vaccine ideally requires an 
understanding of how the agent in question interacts 
with the host to cause disease. Anterograde infection of 
the brain has been proposed in henipavirus infection, as 
well as infection via the systemic route. In addition to 
preventing systemic disease, an ideal vaccine would 
prevent infection of the CNS by either route and thus 
eliminate the possibility of recrudescent CNS disease - 
vaccination against measles virus did reduce the 
incidence of persistent infection manifested as SSPE. 
Clinical trials of a potential vaccine against a BSL-4 
agent could not be carried out in humans; instead there 
is a requirement by the U.S. FDA that candidate 
vaccines be tested in at least two different animal 
models
51
. Relevant animal models that reproduce the 
nervous and systemic aspects of henipavirus infection 
and a thorough understanding of henipavirus 
pathogenesis in these animal models will be essential to 
this activity. To this end, the development of a model 
for henipavirus infection in a non-human primate 
(African green monkey) was an important step, and 
indeed disease progression mediated by either HeV or 
NiV in these animals essentially mirrors that seen in 
humans. Other species that may be suitable include 
golden hamsters, ferrets and cats
52
. 
The strategy for the deployment of successful 
therapeutics is relatively straightforward but a 
successful vaccine may be deployed differently in 
different circumstances. While the outbreaks caused by 
henipa viruses remain sporadic in nature and involve 
relatively small numbers of people and animals (except 
in the NiV outbreak in Malaysia where over one million 
pigs were culled), mass vaccination is unlikely to be a 
viable approach. Vaccination of select human 
populations at risk may be warranted in some 
circumstances; one such population might be, for 
example, horse veterinarians and horse owners in north 
eastern Australia. However, the primary strategy for 
containing HeV outbreaks in Australia is to vaccinate 
horses in at-risk areas. Human infection with HeV is so 
far only known to have occurred via close contact with 
infected horses and so vaccination of horses would 
hopefully prevent the chain of transmission to humans. 
The same principle may apply if for instance, pigs (or 
any other animal) became a significant source of human 
infection, as seen in the initial NiV outbreak in Malaysia 
and Singapore. Should the nature of henipavirus 
outbreaks change or bioterrorism involving these agents 
become a reality then mass vaccination may become a 
viable option
53-54
. 
CONCLUSION 
Recent vaccine studies have demonstrated that 
henipavirus G-specific antibodies are critical for 
protection from disease. Evidence of passive protection 
against NiV, and more recently HeV, challenge using 
hamster polyclonal antiserum or murine (monoclonal 
antibodies) mAbs reactive to NiV glycoproteins was 
provided in the hamster. However, in those prior studies, 
both the challenge virus and antibodies were 
administered by intraperitoneal injection either 
simultaneously or immediately before or following 
challenge. Here we examined a neutralizing fully-human 
mAb, with the potential for human use, in a consistently 
susceptible animal model where challenge and drug 
delivery mimicked a potential real-life scenario. Case 
management should be strengthened in all possible areas 
with proper preventive measures from viral hosts. More 
Studies should be done to assess the vaccines proposed 
and further research on treatment is necessitated. 
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